The abortion pill is not a safe drug. Health Canada issued 40 adverse reaction reports on this drug. Of these, there were 26 individual women.
One woman died.
Two more experienced “life threatening” side effects.
23 women experienced “serious” side effects.
In 2017 there was one woman affected; in 2018 two women were affected; in 2019, it was six women. And in 2020 there were 16 women with serious side effects (Note that the report is only until July 31, 2020, so 2020 will undoubtedly have more serious problems reported).
Notice the trend here? As the abortion pill becomes more popular, even more women will suffer from its life threatening and possibly fatal side effects.
Not a safe drug at all.
The woman who died was 27 years old. From the documented adverse reactions she experienced, it appears that her whole body, and all of her organs, went into extreme failure. Here were her symptoms:
Abdominal pain, Acidosis (a process causing increased acidity in the blood and other body tissues), Ascites (the abnormal buildup of fluid in the abdomen. Technically, it is more than 25 ml of fluid in the peritoneal cavity, although volumes greater than 1 liter may occur) Bacterial infection, Blood pressure decreased, Blood urea increased, Body temperature decreased, Cardiac arrest, Cardiovascular disorder, Chills, Dehydration, Dizziness, Endometritis, Gastritis haemorrhagic, Hyponatraemia (is a low sodium concentration in the blood), Hypoxia (is a condition in which the body or a region of the body is deprived of adequate oxygen supply at the tissue level), Leukocytosis (a condition in which the white cell is above the normal range in the blood. It is frequently a sign of an inflammatory response, most commonly the result of infection), Multiple organ dysfunction syndrome, Nausea, Oliguria (or hypouresis is the low output of urine specifically more than 80 ml/day but less than 400ml/day. The decreased output of urine may be a sign of dehydration, kidney failure, hypovolemic shock, hyperosmolar hyperglycemic nonketotic syndrome, multiple organ dysfunction syndrome, urinary obstruction/urinary retention, diabetic ketoacidosis, pre-eclampsia, and urinary tract infections, among other conditions), Palpitations, Pelvic pain, Pleural effusion (is excess fluid that accumulates in the pleural cavity, the fluid-filled space that surrounds the lungs), Pyrexia (Fever, is defined as having a temperature above the normal range due to an increase in the body’s temperature set point), Sepsis, Septic shock, Uterine spasm, Vaginal discharge, Vaginal haemorrhage, Vomiting
From the data file produced:
CAVEAT: This summary is based on information from adverse reaction reports submitted by health professionals and laypersons either directly to Health Canada or via market authorization holders. Each report represents the suspicion, opinion or observation of the individual reporter. The Canada Vigilance Program is a spontaneous reporting system that is suitable to detect signals of potential health product safety issues during the post-market period. The data has been collected primarily by a spontaneous surveillance system in which adverse reactions to health products are reported on a voluntary basis. Under reporting of adverse reactions is seen with both voluntary and mandatory spontaneous surveillance systems. Accumulated case reports should not be used as a basis for determining the incidence of a reaction or estimating risk for a particular product as neither the total number of reactions occurring, nor the number of patients exposed to the health product is known. Because of the multiple factors that influence reporting, quantitative comparisons of health product safety cannot be made from the data. Some of these factors include the length of time a drug is marketed, the market share, size and sophistication of the sales force, publicity about an adverse reaction and regulatory actions. In some cases, the reported clinical data is incomplete and there is not certainty that these health products caused the reported reactions. A given reaction may be due to an underlying disease process or to another coincidental factor. This information is provided with the understanding that the data will be appropriately referenced and used in conjunction with this caveat statement.